Dapagliflozin reduced heart failure hospitalization and composite CV death regardless of baseline GLA, with greater benefit in baseline GLP‐1 RA users; cardiorenal benefits consistent across baseline therapies. This evidence concerns the gene GLP1R and heart failure.